Literature DB >> 16385404

Chronic Delta9-tetrahydrocannabinol administration affects serotonin levels in the rat frontal cortex.

Onintza Sagredo1, José A Ramos, Javier Fernández-Ruiz, María L López Rodríguez, Rosario de Miguel.   

Abstract

Adult rats were subjected to chronic treatment with the cannabinoid agonist, Delta9-tetrahydrocannabinol, or with vehicle, and their brains used to analyze the contents of serotonin (5HT) and of its intraneuronal metabolite, 5-hydroxyindolacetic acid (5HIAA). 5HT and 5HIAA contents were not affected by chronic cannabinoid administration in most of the brain regions analyzed. We found a marked increase in 5HT contents in the frontal cortex that was accompanied by no changes in 5HIAA contents. This originated a decrease in 5HIAA/5HT ratio, which suggests a possible reduction in the activity of serotoninergic terminals reaching this cortical area. This effect was not seen after an acute injection of this cannabinoid. The relevance of these observations was that they occurred in a region where changes in serotoninergic transmission have been implicated in the development of depression; therefore, our data support the theory that the cannabinoid system might be a potential target for the treatment of this neuropsychiatric disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16385404     DOI: 10.1007/s00210-005-0026-1

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  36 in total

1.  Modulation of cannabinoid agonist binding by 5-HT in the rat cerebellum.

Authors:  Mark G Devlin; Arthur Christopoulos
Journal:  J Neurochem       Date:  2002-03       Impact factor: 5.372

2.  Selective changes in the contents of noradrenaline, dopamine and serotonin in rat brain areas during aging.

Authors:  J M Míguez; M Aldegunde; L Paz-Valiñas; J Recio; E Sánchez-Barceló
Journal:  J Neural Transm (Vienna)       Date:  1999       Impact factor: 3.575

3.  Inhibition of serotonin release in the mouse brain via presynaptic cannabinoid CB1 receptors.

Authors:  M Nakazi; U Bauer; T Nickel; M Kathmann; E Schlicker
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2000-01       Impact factor: 3.000

Review 4.  Pharmacology of cannabinoid CB1 and CB2 receptors.

Authors:  R G Pertwee
Journal:  Pharmacol Ther       Date:  1997       Impact factor: 12.310

Review 5.  Cannabinoids in clinical practice.

Authors:  E M Williamson; F J Evans
Journal:  Drugs       Date:  2000-12       Impact factor: 9.546

Review 6.  Modulation of transmitter release via presynaptic cannabinoid receptors.

Authors:  E Schlicker; M Kathmann
Journal:  Trends Pharmacol Sci       Date:  2001-11       Impact factor: 14.819

7.  Distribution of indoleamines and [3H]paroxetine binding in rat brain regions following acute or perinatal delta 9-tetrahydrocannabinol treatments.

Authors:  F Molina-Holgado; E Molina-Holgado; M L Leret; M I González; T A Reader
Journal:  Neurochem Res       Date:  1993-11       Impact factor: 3.996

Review 8.  Serotonin brain circuits involved in major depression and suicide.

Authors:  Victoria Arango; Mark D Underwood; J John Mann
Journal:  Prog Brain Res       Date:  2002       Impact factor: 2.453

9.  Differential effects of acute cannabinoid drug treatment, mediated by CB1 receptors, on the in vivo activity of tyrosine and tryptophan hydroxylase in the rat brain.

Authors:  David Moranta; Susana Esteban; Jesús A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2004-04-03       Impact factor: 3.000

10.  Behaviorally active doses of the CB1 receptor antagonist SR 141716A increase brain serotonin and dopamine levels and turnover.

Authors:  N A Darmani; J J Janoyan; N Kumar; J L Crim
Journal:  Pharmacol Biochem Behav       Date:  2003-07       Impact factor: 3.533

View more
  14 in total

1.  Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents.

Authors:  Nadia Solowij; Katy A Jones; Megan E Rozman; Sasha M Davis; Joseph Ciarrochi; Patrick C L Heaven; Nicole Pesa; Dan I Lubman; Murat Yücel
Journal:  Psychopharmacology (Berl)       Date:  2011-09-21       Impact factor: 4.530

2.  Differential effects of cannabinoid CB1 inverse agonists and antagonists on impulsivity in male Sprague Dawley rats: identification of a possibly clinically relevant vulnerability involving the serotonin 5HT1A receptor.

Authors:  Peter J McLaughlin; Julia E Jagielo-Miller; Emily S Plyler; Kerry K Schutte; V Kiran Vemuri; Alexandros Makriyannis
Journal:  Psychopharmacology (Berl)       Date:  2017-02-01       Impact factor: 4.530

3.  Cannabinoids Activate Monoaminergic Signaling to Modulate Key C. elegans Behaviors.

Authors:  Mitchell D Oakes; Wen Jing Law; Tobias Clark; Bruce A Bamber; Richard Komuniecki
Journal:  J Neurosci       Date:  2017-02-10       Impact factor: 6.167

4.  Cannabinoids Stimulate the TRP Channel-Dependent Release of Both Serotonin and Dopamine to Modulate Behavior in C. elegans.

Authors:  Mitchell Oakes; Wen Jing Law; Richard Komuniecki
Journal:  J Neurosci       Date:  2019-03-18       Impact factor: 6.167

5.  Genetic deletion of fatty acid amide hydrolase alters emotional behavior and serotonergic transmission in the dorsal raphe, prefrontal cortex, and hippocampus.

Authors:  Francis Rodriguez Bambico; Tommaso Cassano; Sergio Dominguez-Lopez; Noam Katz; Claire Dominique Walker; Daniele Piomelli; Gabriella Gobbi
Journal:  Neuropsychopharmacology       Date:  2010-06-23       Impact factor: 7.853

6.  Inhibition of monoamine oxidase activity by cannabinoids.

Authors:  Zdenek Fisar
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2010-04-18       Impact factor: 3.000

7.  Role of endocannabinoid signaling in anxiety and depression.

Authors:  Sachin Patel; Cecilia J Hillard
Journal:  Curr Top Behav Neurosci       Date:  2009

8.  Δ(9)Tetrahydrocannabinol impairs reversal learning but not extra-dimensional shifts in rhesus macaques.

Authors:  M J Wright; S A Vandewater; L H Parsons; M A Taffe
Journal:  Neuroscience       Date:  2013-01-16       Impact factor: 3.590

9.  Chronic treatment and withdrawal of the cannabinoid agonist WIN 55,212-2 modulate the sensitivity of presynaptic receptors involved in the regulation of monoamine syntheses in rat brain.

Authors:  David Moranta; Susana Esteban; Jesús A García-Sevilla
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-08-16       Impact factor: 3.000

10.  Effect of the CB(1) receptor antagonists rimonabant and AM251 on the firing rate of dorsal raphe nucleus neurons in rat brain slices.

Authors:  Aitziber Mendiguren; Joseba Pineda
Journal:  Br J Pharmacol       Date:  2009-10-20       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.